InsidersTradesSigma
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
无可用的信号评分。
Discover the complete record of transactions filed by Ramachandra Sumant. Director active across 1 company, notably Lyell Immunopharma, Inc.. Cumulatively, 1 filings have been published. Breakdown: 1 buy · 0 sell. Total volume traded: €106k. History available since 21 March 2025. The latest transaction was filed on 21 March 2025 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 条申报中的 1 条